Loading
Loading
Research Overview
Long-acting GLP-1 receptor agonist using palmitoyl-K26 fatty acid modification for albumin binding; stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic GLP-1R signalling.
Liraglutide is a GLP-1 receptor agonist produced by Novo Nordisk, approved in two formulations: Victoza (1.2–1.8 mg daily for type 2 diabetes management) and Saxenda (up to 3.0 mg daily for obesity). Unlike the later weekly GLP-1 agents (semaglutide, tirzepatide), liraglutide requires daily injection due to its shorter 13-hour half-life achieved through albumin-binding fatty acid modification.
Clinical evidence for liraglutide is extensive. The SCALE obesity trial programme demonstrated approximately 5–8% mean body weight reduction with 3.0 mg Saxenda over 56 weeks, with responder analyses showing greater effects in adherent populations. The LEADER cardiovascular outcomes trial with Victoza demonstrated cardiovascular risk reduction in high-risk type 2 diabetes patients — an important milestone establishing the class's cardiometabolic benefits.
Liraglutide was the GLP-1 class predecessor that validated clinical use of GLP-1 agonists for obesity before weekly formulations became the standard of care. Its daily injection burden relative to weekly alternatives represents its primary practical limitation; many patients transition to semaglutide or tirzepatide when access permits.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Prescription availability in Australia and internationally
In Australia, liraglutide (saxenda / victoza) has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
Liraglutide (Saxenda / Victoza) research is most relevant to protocols examining:
Daily GLP-1 agonist dosing research
T2DM and obesity management studies with LEADER trial cardiovascular data
Researchers comparing once-daily vs once-weekly GLP-1 agonist pharmacokinetics
Dose-titration protocol research for GLP-1 tolerability
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: ~13 hours). Review data, confirm baseline recovery before any repeat protocol.
Long-acting GLP-1 receptor agonist using palmitoyl-K26 fatty acid modification for albumin binding; stimulates glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic GLP-1R signalling.
| Parameter | Value |
|---|---|
| Dose range | 0.6 → 3.0 mg/day (titrated |
| Alt. dose 2 | Saxenda) |
| Alt. dose 3 | 0.6 → 1.8 mg/day (Victoza) |
| Schedule | Once daily |
| Route | Subcutaneous |
| Half-life | ~13 hours |
particularly on dose escalation)
rodent data)
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.